CONTERA PHARMA A/S
Core data
Name | CONTERA PHARMA A/S |
Address | Venlighedsvej 4, 2970, Hørsholm |
Founded | Jul 9, 2010 |
| 20 / 19 | |
Locations (P-units) | 1View locations |
Website | https://conterapharma.com/ |
 LinkedIn | contera-pharma |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Name | CONTERA PHARMA A/S |
Address | Venlighedsvej 4, 2970, Hørsholm |
Founded | Jul 9, 2010 |
| 20 / 19 |
Locations (P-units) | 1View locations |
Website | https://conterapharma.com/ |
| LinkedIn | contera-pharma |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Keep track of CONTERA PHARMA A/S
Description
Contera Pharma is a Danish biotech company transforming RNA therapeutics with a proprietary discovery platform that uncovers new opportunities in diseases with significant unmet needs. It develops innovative treatments for neurological disorders.
Contera Pharma uses a precision medicine approach and a proprietary discovery platform to identify human disease-validated drug discovery targets and develop novel therapeutic and pipeline opportunities for neurological disorders. It also pursues partnerships and licensing opportunities.
Company's own description on virk.dk
Description of key activities of the companyLike previous years, the activities are development of new pharmaceuticals and other related activities.
Products & services
Proprietary RNA therapeutics discovery platform · Drug discovery target identification · CP-012 for Parkinson’s disease · CP-102 antisense oligonucleotide therapy for Canavan disease · Research collaborations · Partnering and licensing opportunities
Industries
Biotechnology · Pharmaceutical drug discovery · RNA therapeutics · Neurological disorders
Customer types
Patients with neurological disorders · Academic institutions and companies
Financials
| Reporting period | 2025DKK | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross profit | 20,632,306 | ||||||||
| Operating profit | -5,983,680 | ||||||||
| Profit before tax | -6,062,659 | ||||||||
| Net income | -4,783,781 | ||||||||
| Total assets | 97,550,947 | ||||||||
| Equity | 79,471,802 | ||||||||
| Avg. employees | 14 | ||||||||
2017–2025 Unlock financial history | |||||||||
Datapublica Risk Score
What goes into the assessment
Financials
Equity ratio, profitability, and liquidity
Accounts and history
Late filings and previous financial distress
Owners and management
Past bankruptcies and owners’ other companies
Company and connections
Age, industry, and shared addresses or contact details
Standard: Score and risk bandPro: Also a detailed explanation of the factors
Contact
From conterapharma.com
| Contact | Phone | |
|---|---|---|
| Main | — | in**@conterapharma.comShow full |
Gazelle
Loading gazelle status…
Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.
People
| Person | Roles | Titles |
|---|---|---|
| Paul Ejnar Gremaud Kristjansen | Roles Board | TitlesBESTYRELSESMEDLEM |
| Thomas Nikolaj Sager | Roles BoardManagement | TitlesBESTYRELSESMEDLEM • ADM. DIR. |
Auditor
| Audit firm | Auditor | Role | From |
|---|---|---|---|
| PKF Munkebo Eriksen Funch, Statsautoriseret Revisions aktie selskab | AuditorThomas Funch | RoleStatsautoriseret revisor | FromApr 15, 2026 |
Legal owners
| Owner | Ownership | Voting rights | From |
|---|---|---|---|
Foreign legal entity | Ownership90–99.99 % | Voting rights90 % | FromApr 1, 2024 |
Ultimate owners
| Name | Ownership through | Calculated ownership |
|---|---|---|
| 🇰🇷Bukwang Pharmaceutical Co., Ltd | Ownership through Direct | 90–99.99 % |